- Author:
Yao ZHAO
1
;
Xiaoyu DU
2
;
Yinkai DUAN
1
;
Xiaoyan PAN
3
;
Yifang SUN
4
;
Tian YOU
1
;
Lin HAN
4
;
Zhenming JIN
1
;
Weijuan SHANG
3
;
Jing YU
1
;
Hangtian GUO
1
;
Qianying LIU
4
;
Yan WU
3
;
Chao PENG
5
;
Jun WANG
1
;
Chenghao ZHU
1
;
Xiuna YANG
1
;
Kailin YANG
6
;
Ying LEI
1
;
Luke W GUDDAT
7
;
Wenqing XU
1
;
Gengfu XIAO
3
;
Lei SUN
8
;
Leike ZHANG
9
;
Zihe RAO
10
;
Haitao YANG
11
Author Information
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords: SARS-CoV-2; YM155; drug repurposing; interferon stimulating gene product 15; papain-like protease
- MeSH: Antiviral Agents/therapeutic use*; Binding Sites; COVID-19/virology*; Coronavirus Papain-Like Proteases/metabolism*; Crystallography, X-Ray; Drug Evaluation, Preclinical; Drug Repositioning; High-Throughput Screening Assays/methods*; Humans; Imidazoles/therapeutic use*; Inhibitory Concentration 50; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Naphthoquinones/therapeutic use*; Protease Inhibitors/therapeutic use*; Protein Structure, Tertiary; Recombinant Proteins/isolation & purification*; SARS-CoV-2/isolation & purification*
- From: Protein & Cell 2021;12(11):877-888
- CountryChina
- Language:English
- Abstract: A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M